JPMorgan raised the firm’s price target on PTC Therapeutics (PTCT) to $62 from $51 and keeps an Overweight rating on the shares. The firm updated the company’s model.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics price target raised to $45 from $43 at Barclays
- PTC Therapeutics’ AADC deficiency gene therapy granted FDA approval
- PTC Therapeutics price target raised to $43 from $31 at Barclays
- PTC Therapeutics price target raised to $38 from $33 at TD Cowen
- PTC Therapeutics price target raised to $48 from $44 at Baird